The Asia Pacific lateral flow assay market was valued at US$ 1,271.23 million in 2022 and is expected to reach US$ 2,636.19 million by 2030; it is estimated to register a CAGR of 9.5% from 2022 to 2030.
Evolving Applications of Lateral Flow Assays Boost Asia Pacific Lateral Flow Assay Market
Lateral flow assays are widely used for infectious disease diagnosis, heart disease diagnosis, and veterinary applications. However, the scope of their applications has expanded in recent years. Behavioral health, saliva-based diagnostics, biological warfare (detection of Bacillus anthracis), environmental testing (detection of contaminating enzymes in production facilities), agriculture (detection of genetically modified organisms and quality control of plants), food microbiology (Detection of E. coli O157, Salmonella, Listeria, and other food spoilage bacteria) have emerged as new application areas for lateral flow assays.
Atlas-Link Biotech (Beijing) provides FASPIT Antigen Saliva Test Kit. NOVA Test SARS-CoV-2 Antigen Saliva Test Kit (Colloidal Gold Immunochromatography) is a lateral flow assay that uses the double-antibody sandwich method to detect the SARS-CoV-2 nucleocapsid protein from saliva specimens from patients who are suspected of SARS-CoV-2 by a healthcare provider. Only certified laboratories that meet the requirements for performing moderate, high, or waived complexity tests can perform such saliva-based tests. The SARS-CoV-2 antigen saliva test kits provide preliminary test results, with negative results that don't preclude SARS-CoV-2 infection.
Asia Pacific Lateral Flow Assay Market Overview
Asia Pacific (APAC) lateral flow assay market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia. Countries such as China, Japan, and India are expected to be among the largest contributors to the Asia lateral flow assay market due to rising noncommunicable diseases and increasing market developments. Additionally, the region holds huge potential for the lateral flow assay market players to grow during the forecast period.
China is a developing country in Asia Pacific with a well-established healthcare system and a fast-growing pharmaceutical industry. China is home to various medical, pharmaceutical, and biotechnology product manufacturing companies operating in the global market. These pharmaceutical and biotechnology companies are involved in developing various testing kits and devices for infections and diseases.
Asia Pacific Lateral Flow Assay Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Lateral Flow Assay Market Segmentation
The Asia Pacific lateral flow assay market is categorized into product type, technique, test type, application, end user, and country.
Based on product type, the Asia Pacific lateral flow assay market is bifurcated into kits & reagents and lateral flow readers. The kits & reagents segment held a larger Asia Pacific lateral flow assay market share in 2022.
In terms of technique, the Asia Pacific lateral flow assay market is segmented into sandwich assay, competitive assays, and multiplex detection assay. The sandwich assay segment held the largest Asia Pacific lateral flow assay market share in 2022.
By test type, the Asia Pacific lateral flow assay market is divided into lateral flow immunoassay and nucleic acid lateral flow assay. The lateral flow immunoassay segment held a larger Asia Pacific lateral flow assay market share in 2022.
Based on application, the Asia Pacific lateral flow assay market is categorized into clinical testing, veterinary diagnostics, food safety & environment testing, and drug development & quality testing. The clinical testing segment held the largest Asia Pacific lateral flow assay market share in 2022.
By end user, the Asia Pacific lateral flow assay market is segmented into hospitals and clinics, diagnostics laboratories, homecare, veterinary clinics, pharmaceutical & biotechnology companies, and others. The hospitals and clinics segment held the largest Asia Pacific lateral flow assay market share in 2022.
By country, the Asia Pacific lateral flow assay market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific lateral flow assay market share in 2022.
F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Becton Dickinson and Co, PerkinElmer Inc, Hologic Inc, QIAGEN NV, bioMerieux SA, QuidelOrtho Corp, Abbott Laboratories, Merck KGaA, Bio-Rad Laboratories Inc, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific lateral flow assay market.
1. F. Hoffmann-La Roche Ltd
2. Siemens Healthineers AG
3. Becton Dickinson and Co
4. PerkinElmer Inc
5. Hologic Inc
6. QIAGEN NV
7. bioMerieux SA
8. QuidelOrtho Corp
9. Abbott Laboratories
10. Merck KGaA
11. Bio-Rad Laboratories Inc
12. Thermo Fisher Scientific Inc